Home
overview
If you want to keep up to date with the recent developments and advances in oncology research, the easiest way is to attend SMi’s Research Based Oncology conference. SMi’s event offers you the simple way to stay ahead of the game, by covering the latest hot topics in cancer research and the progression of ongoing studies.

The conference aims to show how greater comprehension of cancer molecular biology will lead to new treatments based on specific genetic and phenotypic abnormalities in cancer cells. It will bring together leaders in the fields of biotechnology and pharmaceutical development to share up to date information about the application of oncology research in medicine, and to analyse the future of the industry.

Why you should attend this event? As a senior industry executive, you will be aware of the importance and potential of this field. This conference offers you the opportunity to discover the potential and realities of oncology research, to match your company’s resources to the needs of drug discovery.

Plus a one day pre conference workshop 16th October 2001, The Hatton, London In association with CoMed Communications

Medical Education and Communications in Oncology Research, Development, and Marketing

An Interactive Workshop Featuring Audience Response and Participation

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Lars Breimer

Dr Lars Breimer, Clinical Science Leader, Global Drug Development, F. Hoffmann-La Roche

9:10 DEVELOPMENTS IN RESEARCH BASED ONCOLOGY

Professor Toshihisa Ishikawa

Professor Toshihisa Ishikawa, , Tokyo Institute of Technology

  • Targeting cancerous cells effectively
  • Recent developments in multidrug treatments
  • Human multidrug resistance-associated protein (MRP)
  • P-glycoproteins and other ABC proteins
  • Is transport mechanism-based drug molecular design possible?
  • 9:40 CHEMOPREVENTION

    Dr Jillian Evans

    Dr Jillian Evans, Director, Pharmacology, Merck Research Laboratories

  • Colon cancer: familial and sporadic
  • COX-2 inhibitors and cancer prevention
  • Vioxx:chemoprevention of colon cancer
  • Market size and demographics
  • Future prospects for COX-2 inhibitors in other cancers
  • 10:20 NEW WEAPONS IN THE CANCER WAR

    Dr Lars Breimer

    Dr Lars Breimer, Clinical Science Leader, Global Drug Development, F. Hoffmann-La Roche

  • Molecular biology of the cell cycle
  • Dysregulation of cell growth in cancer
  • Impact of cell surface signalling on the cell cycle
  • Check-points and components as novel targets
  • Potential of the new classes of drugs in clinical trials
  • 11:00 Morning Coffee

    11:20 PROTEIN KINASE INHIBITORS

    Dr Doriano Fabbro

    Dr Doriano Fabbro, Head, In vitro Lead Profiling, Oncology Research, Novartis

  • Cyclin-dependent protein kinases, EGF-R/VEGFR and Abl kinases
  • Protein phosphorylation
  • Antiproliferative and antiangiogenic
  • Growth factors and receptor tyrosine kinases
  • Animal models
  • Control of multi-genic diseases: applications in cancer
  • 12:00 SIGNAL TRANSDUCTION AND PROTEIN KINASE INHIBITORS

    Dr Jasbinder Sanghera

    Dr Jasbinder Sanghera, Chief Scientific Officer, Kinetekpharm

  • Blocking components of PI-3-K signalling pathway
  • Inhibiting ILK and PKB mediated signal transduction
  • Dysregulation of ILK and PKB in human tumors
  • In vivo efficacy in xenograft models with ILK and PKB inhibitors
  • 12:40 Lunch

    13:40 SELECTIVE APOPTOSIS: cGMP PHOSPHODIESTERASE INHIBITION

    Dr Rifat Pamukcu

    Dr Rifat Pamukcu, Co-Founder, Chief Scientific Officer, Executive Vice President, Research & Development, Cell Pathways

    14:20 TUMOUR IMMUNOTHERAPY

    Dr Miles Carroll

    Dr Miles Carroll, Vice President of Immunotherapy, Oxford BioMedica (UK) Ltd

  • Tumour Antigen evaluation
  • Pre-clinical studies
  • Clinical protocol for colorectal cancer
  • 15:00 RECEPTOR BINDING

    Dr Francesc Mitjans

    Dr Francesc Mitjans, Project Leader, Merck Farma y Quimica

  • Human malignant melanoma therapies
  • The vitronectin receptor – survival signals
  • Role in melanoma progression and in tumor angiogenesis
  • Antagonists: as anti tumour drugs in vivo
  • hMAb’s

    17E6

  • Cyclic RGD

    Therapeutic potential

  • 15:40 Afternoon Tea

    16:00 ADVANCED DATA MINING FOR EX[RESSION-BASED CANCER DRUG SCREENING

    Dr Rowland Somogyi

    Dr Rowland Somogyi, CSO, Molecular Mining Corporation

    16:30 AGENT (ANTIBODY-GUIDED ENZYME NITRILE THERAPY)

    Dr Mahendra Deonarain

    Dr Mahendra Deonarain, Lecturer, Imperial College & Consultant, Antisoma, Imperial College University of London & Antisoma

  • Recent advanced in antibody engineering
  • Natural cyanogenesis
  • Targeted cyanogenesis
  • Recombinant production of fusion proteins
  • In vitro characterisation
  • Future developments
  • 17:10 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr John Herrmann

    Dr John Herrmann, Project Leader, Oncology Program, CuraGen

    9:10 NEW APPROACHES IN IMMUNOLOGY

    Dr Polly Matzinger

    Dr Polly Matzinger, Section Head, T Cell Tolerance and Memory Section, National Institute of Allergy & Infectious Diseases, National Institute of Health

  • What turns an immune response on & off?
  • Do we need adjuvants?
  • Why do mothers not reject their fetuses?
  • Why are transplants rejected while tumors are not?
  • 9:40 IMMUNOTHERAPY OF CANCER

    Dr David Urdal

    Dr David Urdal, President & Chief Scientific Officer, Dendreon

  • Antigen presenting cells as vehicles
  • Pre clinical studies
  • Genetically engineered antigens for optimal processing by dendritic cells
  • Clinical experience in prostate cancer, multiple myeloma and breast cancer
  • 10:20 ANTI-CANCER TARGET DISCOVERY

    Dr John Herrmann

    Dr John Herrmann, Project Leader, Oncology Program, CuraGen

  • A case for being unbiased
  • Open Architecture Technologies for the dissection of the cancer genome
  • Scanning the genome for new targets
  • Attacking the pharmaceutically tractable genome
  • Data integration to accelerate target discovery
  • Pathway mapping to de-orphanize druggable targets

    Triaging pre-clinical candidates

  • 11:00 Morning Coffee

    11:20 CANCER: THE DISEASE OF THE GENOME

    Dr Mark Rolfe

    Dr Mark Rolfe, Director, Molecular & Cellular Oncology Department, Millennium Pharmaceuticals

  • The new era of oncology
  • The new investigative arsenal · genome-based information technologies · genomics-related experimental technologies
  • Deciphering the bio-molecular characteristics of proliferative diseases.
  • Understanding the mechanisms and molecular characteristics of different cancers
  • New opportunities for target discovery and improvements in oncology drug discovery
  • Fulfilment of genomic technologies promise to improve the diagnosis and treatment of cancer
  • 12:00 BRINGING THE DREAM ONE STEP CLOSER TO REALITY

    Dr James McArthur

    Dr James McArthur, Principal Scientist & Senior Director, Preclinical Biology & Immunology, Principal Scientist & Senior Director, Preclinical Biology & Immunology

  • AV, AAV and lentiviral vectors for anti-angiogenic gene therapy
  • p27-p16 gene therapy
  • Angiostatin/endostatin gene therapy
  • Modelling anti-angiogenic gene therapy
  • 12:40 Lunch

    14:00 ANTISENSE OLIGONUCLEOTIDES

    Dr Jim Wright

    Dr Jim Wright, Chief Executive Officer, Lorus Therapeutics

  • Anti-sense technology
  • Blocking growth and cell cycle related genes
  • Pre – clinical studies
  • Clinical trials
  • The future of antisense technology
  • 14:40 ANTI – ANGIOGENIC STRATEGIES FOR CANCER THERAPY

    Dr Donald Bottaro

    Dr Donald Bottaro, Director, Department, Cell & Molecular Biology, EntreMed

  • Overview of anti-angiogenic strategies
  • Proteins and small molecules as anti-angiogenic agents
  • Advances in vaccine research
  • Ongoing preclinical research
  • Clinical research update
  • 15:20 Afternoon Tea

    15:40 MONOCLONAL ANTIBODIES TARGETING VEGF

    Dr Hanspeter Gerber

    Dr Hanspeter Gerber, Scientist, Genentech

  • Recent advances in therapeutic MAb's in oncology
  • Data update: neutralizing antibody against VEGF
  • Development: anti-VEGF and bone growth
  • Tumor models: anti-VEGF and tumor growth and metastasis
  • Update on the phase II and III clinical data
  • How does VEGF regulate hematopoiesis?
  • 16:20 ANTI-ANGIOGENESIS AND ANTI-CANCER STRATEGIES

    Dr Peter Bohlen

    Dr Peter Bohlen, Senior Vice President, Research, ImClone Systems

  • KDR antibody phase 1 study
  • KDR antibody efficacy in a leukemia model
  • Anticancer therapeutic potential of VEGFR1 (flt1)
  • Anti-angiogenic and anti-cancer activity of flt1 antibody
  • VEGF receptor antibodies in a model of atherosclerosis
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.